Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
NCT05254990 · Dompé Farmaceutici S.p.A · PHASE3 · terminated · last registry update 2026-02-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped due to futility as per protocol” | – | Registry record, Dompé Farmaceutici S.p.A |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-31Results posted on the registry: Dompé Farmaceutici S.p.A, Ladarixin + Placebo (NCT04628481)
- 2026-08-31Also stopped (terminated): Dompé Farmaceutici S.p.A, Ladarixin + Placebo (NCT04628481)
- 2026-05-11Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin 600mg (NCT05496868)
- 2025-05-14Results posted on the registry: Dompé Farmaceutici S.p.A, Ladarixin (NCT04899271)
- 2025-05-14Also stopped (terminated): Dompé Farmaceutici S.p.A, Ladarixin (NCT04899271)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision